In Brief: Aastrom Biosciences
This article was originally published in The Gray Sheet
Aastrom Biosciences: Ann Arbor, Michigan-based firm gains approval of an investigational device exemption to begin trials on its first product, the Aastrom cell production system (CPS). The system is designed to produce cells for blood and immune system recovery after chemotherapy involving bone marrow transplantation ("The Gray Sheet" Nov. 15, 1994, p. 3). The Phase I trial will involve up to ten breast cancer patients at the M.D. Anderson Cancer Center in Houston, Texas. The firm also is developing Gene Loader technology for delivery of genes into human cells and tissue...
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.